药物洗脱支架在预防支架内再狭窄中的作用及临床应用进展-东南大学学报医学版

药物洗脱支架在预防支架内再狭窄中的作用及临床应用进展

单位：东南大学,医学院,江苏,南京,210009

分类号：R541.4

出版年·卷·期（页码）：2005·24·第二期（122-125）

摘要：

冠状动脉支架植入术已成为冠心病治疗中一种有确切疗效的重要手段,但相当高(10%～50%)的支架内再狭窄率限制了支架植入术的发展.而可在局部缓慢释放抑制血管内皮和平滑肌增殖药物的药物洗脱支架(DES)的应用,明显降低了支架内再狭窄率,大大延缓了支架术后再次行经皮冠状动脉介入治疗的时间.目前临床应用的DES有雷帕霉素洗脱支架和紫杉醇洗脱支架,其显著降低支架内再狭窄率的作用已为越来越多的已完成或正在进行的临床试验所证实.

Percutaneous coronary stenting has become a major method in coronary heart disease treatment with exact efficacy . But higher in-stent restenosis rate (about 10%-50%) hampered its development. Recent usage of drug-eluting stent(DES) dramatically decreased the in-stent restenosis rate and postponed additional percutanenous coronary intervention(PCI) by giving off antiproliferative agents slowly on smooth muscle cells and endothelial cells. CypherTM stent and TaxusTM stent were the only DESs in clinical use now days, and their positive effects have been proved by more and more clinical trials.

参考文献：

[1] HOFFMANN R, MINTZ G S, DUSSAILLANT G R. Partterns and mechanisms of instent restenosis. A serial intravascular ultrasound study, 1996
[2] MINTZ G S, POPMA J J, PICHARD A D. Arterial remodeling after coronary angioplasty:a serial intravascular ultrasound study, 1996
[3] RON W. Drug-eluting stents:from bench to bed, 2002
[4] WINDECKER S, MAYER I, de PASQUALE G. Stent-coating with titanium- nitride- oxide for reduction of neointimal hyperplasia. 2001(8). doi:10.1161/hc3401.093146
[5] LIU X, HUANG Y, HANET C. Study of antirestenosis with the Biodiv Ysio dexamethasone-eluting stent(STRIDE):a first-inhuman multienter pilot trial, 2003
[6] SWANSON N, HOGREFEK K, JAVED Q. Vascular endothe lial growth facter(VEGF)-eluting stents:in vivo effects on thrombosis,endothelialization and intimal hyperplasia, 2003(12)
[7] CHANDRASEKAR B, TANGUAY J F. First human experience with the 17-beta-estradiol-eluting stent, 2000(6)
[8] HEINRICH W, OLAT D, THOMAS S. Synergistic effects of a noval nanoporous stent coating and tacrolimus on intima proliteration in rabbits. 2003
[9] MCKEAGE K, MURDOCH D, GOA K L. The sirolimus- eluting stent:a review of its use in the treatment of coronary artery disease. 2003(3). doi:10.2165/00129784-200303030-00007
[10] DEGERTKIN M, SERRUYS P W, TANABE K. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions:an intravascular ultrasound analysis. 2003(22). doi:10.1161/01.CIR.0000103666.25660.77
[11] TAXUS-Ⅳ Study Group. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. 2003(7). doi:10.1161/01.CIR.0000086926.62288.A6
[12] GERSHLICK A, de SCHEERDER I, CHEVALIER B. Inhibitian of restenosis with a paclitaxel-eluting,polymer-free coronary stent:the European evaluation of paclitaxel-eluting stent(ELUTES)trial. 2004(4). doi:10.1161/01.CIR.0000109694.58299.A0
[13] GRUBE E, BUELLESFELD L. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. 2004(2). doi:10.1007/s00059-004-2556-6
[14] BUELLESFELD L, GRUBE E. ABT- 578 - eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?. 2004(2). doi:10.1007/s00059-004-2557-5

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录